Asset Advisors Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.8M | Sell |
94,611
-1,214
| -1% | -$261K | 2.18% | 14 |
|
|
2026
Q1 | $20.8M | Sell |
95,825
-262
| -0.3% | -$58.1K | 1.99% | 16 |
|
|
2025
Q4 | $22M | Buy |
96,087
+39
| +0% | +$8.88K | 2.03% | 16 |
|
|
2025
Q3 | $22.2M | Buy |
96,048
+1,507
| +2% | +$307K | 2.11% | 15 |
|
|
2025
Q2 | $17.5M | Sell |
94,541
-137
| -0.1% | -$25.5K | 1.73% | 18 |
|
|
2025
Q1 | $19.8M | Sell |
94,678
-400
| -0.4% | -$77.8K | 2.08% | 16 |
|
|
2024
Q4 | $16.9M | Sell |
95,078
-2,245
| -2% | -$413K | 1.77% | 19 |
|
|
2024
Q3 | $19.2M | Sell |
97,323
-495
| -0.5% | -$92.4K | 2% | 14 |
|
|
2024
Q2 | $16.8M | Buy |
97,818
+5,417
| +6% | +$897K | 1.83% | 17 |
|
|
2024
Q1 | $16.8M | Buy |
92,401
+2,982
| +3% | +$514K | 1.89% | 17 |
|
|
2023
Q4 | $13.9M | Buy |
89,419
+799
| +0.9% | +$116K | 1.69% | 21 |
|
|
2023
Q3 | $13.2M | Sell |
88,620
-1,067
| -1% | -$157K | 1.78% | 18 |
|
|
2023
Q2 | $12.1M | Sell |
89,687
-2,650
| -3% | -$389K | 1.54% | 22 |
|
|
2023
Q1 | $14.7M | Buy |
92,337
+92
| +0.1% | +$14.1K | 1.93% | 17 |
|
|
2022
Q4 | $14.9M | Sell |
92,245
-600
| -0.6% | -$92K | 1.96% | 16 |
|
|
2022
Q3 | $12.5M | Sell |
92,845
-225
| -0.2% | -$32.3K | 1.78% | 17 |
|
|
2022
Q2 | $14.3M | Sell |
93,070
-3,550
| -4% | -$542K | 1.94% | 15 |
|
|
2022
Q1 | $15.7M | Buy |
96,620
+4,225
| +5% | +$614K | 1.75% | 20 |
|
|
2021
Q4 | $12.5M | Sell |
92,395
-3,700
| -4% | -$437K | 1.26% | 27 |
|
|
2021
Q3 | $10.4M | Sell |
96,095
-13,485
| -12% | -$1.54M | 1.16% | 29 |
|
|
2021
Q2 | $12.3M | Buy |
109,580
+2,000
| +2% | +$225K | 1.37% | 26 |
|
|
2021
Q1 | $11.6M | Sell |
107,580
-50
| -0% | -$5.35K | 1.35% | 26 |
|
|
2020
Q4 | $11.5M | Buy |
107,630
+4,918
| +5% | +$473K | 1.49% | 23 |
|
|
2020
Q3 | $9M | Sell |
102,712
-2,702
| -3% | -$254K | 1.36% | 24 |
|
|
2020
Q2 | $10.3M | Sell |
105,414
-1,366
| -1% | -$120K | 1.65% | 19 |
|
|
2020
Q1 | $8.14M | Sell |
106,780
-2,230
| -2% | -$190K | 1.51% | 24 |
|
|
2019
Q4 | $9.62M | Buy |
109,010
+8,990
| +9% | +$746K | 1.4% | 24 |
|
|
2019
Q3 | $7.57M | Buy |
100,020
+2,075
| +2% | +$142K | 1.21% | 28 |
|
|
2019
Q2 | $7.12M | Buy |
97,945
+855
| +0.9% | +$67.2K | 1.2% | 29 |
|
|
2019
Q1 | $7.82M | Buy |
97,090
+350
| +0.4% | +$28.6K | 1.39% | 23 |
|
|
2018
Q4 | $8.92M | Buy |
96,740
+1,430
| +2% | +$126K | 1.77% | 18 |
|
|
2018
Q3 | $9.01M | Buy |
+95,310
| New | +$9.04M | 1.49% | 21 |
|
Other funds holding ABBV
Asset Advisors Investment Management's ABBV Position: Q2 2026 in Review
Asset Advisors Investment Management reduced its AbbVie (ABBV) stake by 1.3% in Q2 2026, selling an estimated $261K and leaving 94,611 shares worth $23.8M. The position accounts for 2.18% of the portfolio, ranked #14.
Asset Advisors Investment Management first reported a position in ABBV in Q3 2018 and has held it in 32 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Asset Advisors Investment Management held 94,611 shares of AbbVie worth $23.8M as of Q2 2026.
- Asset Advisors Investment Management sold 1,214 AbbVie shares in Q2 2026, an estimated $261K.
- AbbVie made up 2.18% of Asset Advisors Investment Management's portfolio in Q2 2026, its #14 holding.
- Asset Advisors Investment Management first reported a position in AbbVie in Q3 2018 and has held it in 32 quarters since.
- 4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Asset Advisors Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.